BMC Psychiatry (Apr 2023)

Measurement invariance of the PHQ-9 and GAD-7 across males and females seeking treatment for common mental health disorders

  • Rob Saunders,
  • Delilah Moinian,
  • Joshua Stott,
  • Henry Delamain,
  • Syed Ali Naqvi,
  • Satwant Singh,
  • Jon Wheatley,
  • Stephen Pilling,
  • Joshua E.J. Buckman

DOI
https://doi.org/10.1186/s12888-023-04804-x
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background The nine-item Patient Health Questionnaire (PHQ-9) and the seven-item Generalised Anxiety Disorder scale (GAD-7) are routinely used in research and clinical practice. Whilst measurement invariance of these measures across gender has been demonstrated individually in general population studies and clinical samples, less is known about invariance of the distinct but correlated latent factors (‘depression’ and ‘anxiety’). The current study assessed measurement invariance of these constructs across males and females seeking treatment for common mental health disorders. Methods Data were provided from eight psychological treatment services in London, England. Data from initial assessments with the services where individual items on the PHQ-9 and GAD-7 were available were included in analyses. Measurement invariance was explored across self-identified genders, with ‘male’ and ‘female’ categories available in the dataset. Sensitivity analyses were conducted using propensity score matching on sociodemographic and clinical variables. Results Data were available for 165,872 patients (110,833 females, 55,039 males). There was evidence of measurement invariance between males and females in both the full sample and a propensity score matched sample (n = 46,249 in each group). Conclusions Measurement invariance of the correlated depression and anxiety factors of PHQ-9 and GAD-7 were indicated in this sample of individuals seeking psychological treatment for CMHDs. These results support the use of these measures in routine clinical practice for both males and females. This is of particular importance for assessing the prevalence of clinically significant levels of symptoms as well as comparing treatment outcomes across genders.

Keywords